Expert Opinion on Investigational Drugs

Acetyl-L-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?
pp. 827-843(17)
Authors: Soczynska, Joanna K; Kennedy, Sidney H; Chow, Cindy SM; Woldeyohannes, Hanna O; Konarski, Jakub Z; McIntyre, Roger S

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
pp. 845-853(9)
Author: Mikhail, Nasser

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress
pp. 855-864(10)
Authors: Gur, Serap; Sikka, Suresh C; Hellstrom, Wayne JG

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check
pp. 865-878(14)
Authors: O'Hare, Thomas; Eide, Christopher A; Deininger, Michael W

The potential of proteasome inhibitors in cancer therapy
pp. 879-895(17)
Authors: Sterz, Jan; Metzler, Ivana von; Hahne, Jens-Claus; Lamottke, Britta; Rademacher, Jessica; Heider, Ulrike; Terpos, Evangelos; Sezer, Orhan

Pompholyx: what's new?
pp. 897-904(8)
Author: Wollina, Uwe

The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy
pp. 905-916(12)
Authors: Gharaee-Kermani, Mehrnaz; Hu, Biao; Phan, Sem H; Gyetko, Margaret R

Trans-sodium crocetinate for treating hypoxia/ischemia
pp. 917-924(8)
Author: Gainer, John L

Rivaroxaban, an oral direct factor Xa inhibitor
pp. 925-937(13)
Authors: Piccini, Jonathan P; Patel, Manesh R; Mahaffey, Kenneth W; Fox, Keith AA; Califf, Robert M

Enzastaurin
pp. 939-944(6)
Authors: Chen, Yi-Bin; LaCasce, Ann S

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel
pp. 945-951(7)
Authors: Mardini, Houssam E; de Villiers, Willem JS

Mecobalamin
pp. 953-964(12)
Authors: Zhang, Yi-Fei; Ning, Guang

PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport?
pp. 965-968(4)
Author: Antoniu, Sabina A